MP17-10 DEVELOPMENT AND UTILIZATION OF AN AT HOME URINE EXOSOME BIOMARKER COLLECTION TEST KIT TO SUPPORT UROLOGIC TELEHEALTH

Abstract

You have accessJournal of UrologyCME1 Apr 2023MP17-10 DEVELOPMENT AND UTILIZATION OF AN AT HOME URINE EXOSOME BIOMARKER COLLECTION TEST KIT TO SUPPORT UROLOGIC TELEHEALTH Ali Kasraeian, David Albala, Grannum Sant, Judd Moul, Liam Hurley, Sanoj Punnen, Jason Alter, and Ronald Tutrone Ali KasraeianAli Kasraeian More articles by this author , David AlbalaDavid Albala More articles by this author , Grannum SantGrannum Sant More articles by this author , Judd MoulJudd Moul More articles by this author , Liam HurleyLiam Hurley More articles by this author , Sanoj PunnenSanoj Punnen More articles by this author , Jason AlterJason Alter More articles by this author , and Ronald TutroneRonald Tutrone More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003237.10AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: COVID-19 led to paradigm shifts in telemedicine due to patient’s fear of office visits and travel avoidance. With widespread cancellation of office visits and reduction of diagnostic biopsy procedures in men with elevated PSAs, the need for a non-invasive/non-DRE At Home Collection Kit for assessing risk of aggressive prostate cancer and to prioritize biopsy procedures became apparent. We adapted the existing ExoDx Prostate (EPI) office liquid biomarker kit into an At Home Collection Kit physician/patient shared decisions for prostate biopsy. METHODS: A 2-stage program for an At Home Collection Testing Kit program for the ExoDx Test was initiated in April 2020 at the onset of the COVID-19 pandemic. The Phase 1 Pilot study (100 patients, 6 sites) was completed in June 2020. Based on the findings in the pilot, the program was streamlined based on feedback from physicians, patients, and office mangers before making it available in Phase 2 to all urologists in the US. The utilization of the At Home Collection Kits have been measured. RESULTS: Extensive feedback from the pilot program led to improvements and streamlining before the Phase 2 rollout. As of October 31st, 2022, >30% of all the ExoDx Prostate Tests are At Home Collection Kits. EPI Score distributions are identical (mean 28.4 and 29.7), (median 23.0 and 24.7) in home or clinic sample collection respectively (Figure 1). CONCLUSIONS: The COVID-19 pandemic accelerated major shifts to telehealth and increased use of At Home Testing. The ExoDx Prostate (EPI) At Home Collection Kit was successfully developed and employed to help men (>50 years old) with elevated PSAs (2 – 10 ng/ml) considering initial or repeat diagnostic biopsy but with pandemic-related fears of visiting offices/hospitals or wanting to avoid long distance travel from rural areas. As COVID becomes manageable and clinical practices have opened, some pandemic-adopted approaches remain relevant: the ExoDx™ Prostate, (EPI) At Home Collection Kit is one such approach. Source of Funding: Exosome Diagnostics, a Bio-Techne Brand, Waltham, MA © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e216 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Ali Kasraeian More articles by this author David Albala More articles by this author Grannum Sant More articles by this author Judd Moul More articles by this author Liam Hurley More articles by this author Sanoj Punnen More articles by this author Jason Alter More articles by this author Ronald Tutrone More articles by this author Expand All Advertisement PDF downloadLoading ...